Journal article
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Abstract
BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption.
METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, …
Authors
Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A
Journal
The New England Journal of Medicine, Vol. 375, No. 16, pp. 1532–1543
Publisher
Massachusetts Medical Society
Publication Date
October 20, 2016
DOI
10.1056/nejmoa1607948
ISSN
0028-4793